230 related articles for article (PubMed ID: 12458647)
1. Obesity, cardiovascular risk and pharmacotherapy.
Ruilope LM; Garcia-Robles R; Moreno B
Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
[No Abstract] [Full Text] [Related]
2. [Anti-obesity drugs: sibutramine and orlistat].
Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
[No Abstract] [Full Text] [Related]
3. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of obesity: pharmacology .
Finer N
Proc Nutr Soc; 2000 Aug; 59(3):413. PubMed ID: 10997657
[No Abstract] [Full Text] [Related]
5. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
Toubro S
Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
[No Abstract] [Full Text] [Related]
7. The new role of pharmacotherapy for weight reduction in obesity.
Fernstrom MH; Fernstrom JD
Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
[TBL] [Abstract][Full Text] [Related]
8. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
Verspohl EJ
Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
[No Abstract] [Full Text] [Related]
9. Pharmacological therapy of obesity: past, present, and future.
Weigle DS
J Clin Endocrinol Metab; 2003 Jun; 88(6):2462-9. PubMed ID: 12788841
[No Abstract] [Full Text] [Related]
10. [Pharmacotherapy of obesity].
Svendsen OL
Ugeskr Laeger; 2004 Oct; 166(43):3814-7. PubMed ID: 15544112
[No Abstract] [Full Text] [Related]
11. New pharmacological directions for the treatment of overweight and obesity.
Van Gaal LF; Peiffer FW; De Leeuw IH
Acta Clin Belg; 1999 Jun; 54(3):141-6. PubMed ID: 10443041
[No Abstract] [Full Text] [Related]
12. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Madsbad S
Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
[TBL] [Abstract][Full Text] [Related]
13. [No progress without the physician in therapy of obesity].
Schmidt H; Plauth M
MMW Fortschr Med; 2000 Jan; 142(4):35-6. PubMed ID: 10850095
[No Abstract] [Full Text] [Related]
14. Orlistat for obesity.
Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
[No Abstract] [Full Text] [Related]
15. [A drug help in reducing? Risk profile decides whether and how].
Hauner H
MMW Fortschr Med; 2003 May; 145(21):60. PubMed ID: 12845877
[No Abstract] [Full Text] [Related]
16. [New drugs for the treatment of obesity].
Mustajoki P
Duodecim; 1999; 115(20):2191, 2193-4. PubMed ID: 11973921
[No Abstract] [Full Text] [Related]
17. Long-term pharmacotherapy for obesity.
Klein S
Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
[TBL] [Abstract][Full Text] [Related]
18. [Drug treatment of obesity].
Burniat W
Rev Med Brux; 2009; 30(2):124-6. PubMed ID: 19517912
[No Abstract] [Full Text] [Related]
19. Incorrect use of orlistat and sibutramine in clinical practice.
Dahlin A; Beermann B
Eur J Clin Pharmacol; 2007 Feb; 63(2):205-9. PubMed ID: 17205321
[TBL] [Abstract][Full Text] [Related]
20. Obesity and cardiovascular physiology: impact of some pharmacological agents.
Chaput JP; Bérubé-Parent S; Tremblay A
Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
